Bridging the Survival Gap: A Retrospective Study Comparing Docetaxel, Abiraterone, and Enzalutamide in Black and White Men with Metastatic Prostate Cancer in the Veterans Affairs System

Summary: Prostate cancer remains the most common type of cancer in men, with notable disparities in outcomes based on race and socioeconomic factors. Black men with prostate cancer tend to be diagnosed at an earlier age and are diagnosed with more aggressive disease. The primary goal of this analysis was to compare overall survival of black and white men with metastatic disease who are receiving either abiraterone, docetaxel, or enzalutamide as the first line of therapy.